Literature DB >> 12519300

Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

Isabel Correa1, Tim Plunkett, Anda Vlad, Arron Mungul, Jessica Candelora-Kettel, Joy M Burchell, Joyce Taylor-Papadimitriou, Olivera J Finn.   

Abstract

MUC1 is a transmembrane mucin that is expressed on ductal epithelial cells and epithelial malignancies and has been proposed as a target antigen for immunotherapy. The expression of MUC1 has recently been reported on T and B cells. In this study we demonstrate that following activation in vivo or activation by different stimuli in vitro, human T cells expressed MUC1 at the cell surface. However, the level of expression in activated human T cells was significantly lower than that seen on normal epithelial cells or on breast cancer cells. In contrast, resting T cells did not bind MUC1-specific monoclonal antibodies (mAbs), nor was MUC1 mRNA detectable by reverse transcription-polymerase chain reaction (RT-PCR) or Northern blot analysis in these cells. The profile of activated T-cell reactivity with different MUC1-specific antibodies suggested that the glycoform of MUC1 expressed by the activated T cells carried core 2-based O-glycans, as opposed to the core 1 structures that dominate in the cancer-associated mucin. Confocal microscopy revealed that MUC1 was uniformly distributed on the surface of activated T cells. However, when the cells were polarized in response to a migratory chemokine, MUC1 was found on the leading edge rather than on the uropod, where other large mucin-like molecules on T cells are trafficked. The concentration of MUC1 at the leading edge of polarized activated human T cells suggests that MUC1 could be involved in early interactions between T cells and endothelial cells at inflammatory sites.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519300      PMCID: PMC1782871          DOI: 10.1046/j.1365-2567.2003.01562.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  50 in total

1.  Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.

Authors:  L Carmon; K M El-Shami; A Paz; S Pascolo; E Tzehoval; B Tirosh; R Koren; M Feldman; M Fridkin; F A Lemonnier; L Eisenbach
Journal:  Int J Cancer       Date:  2000-02-01       Impact factor: 7.396

2.  Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

Authors:  S von Mensdorff-Pouilly; A A Verstraeten; P Kenemans; F G Snijdewint; A Kok; G J Van Kamp; M A Paul; P J Van Diest; S Meijer; J Hilgers
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyllactosamine backbones with Gal beta(1-4)GlcNAc beta(1-6) repeating units.

Authors:  F G Hanisch; G Uhlenbruck; J Peter-Katalinic; H Egge; J Dabrowski; U Dabrowski
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

4.  Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin.

Authors:  D Nath; A Hartnell; L Happerfield; D W Miles; J Burchell; J Taylor-Papadimitriou; P R Crocker
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

5.  Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells.

Authors:  K O Lloyd; J Burchell; V Kudryashov; B W Yin; J Taylor-Papadimitriou
Journal:  J Biol Chem       Date:  1996-12-27       Impact factor: 5.157

6.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

Authors:  K R Jerome; D L Barnd; K M Bendt; C M Boyer; J Taylor-Papadimitriou; I F McKenzie; R C Bast; O J Finn
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

7.  Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

Authors:  E van de Wiel-van Kemenade; M J Ligtenberg; A J de Boer; F Buijs; H L Vos; C J Melief; J Hilkens; C G Figdor
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

Review 8.  MUC-1 epithelial tumor mucin-based immunity and cancer vaccines.

Authors:  O J Finn; K R Jerome; R A Henderson; G Pecher; N Domenech; J Magarian-Blander; S M Barratt-Boyes
Journal:  Immunol Rev       Date:  1995-06       Impact factor: 12.988

9.  Does pregnancy immunize against breast cancer?

Authors:  B Agrawal; M A Reddish; M J Krantz; B M Longenecker
Journal:  Cancer Res       Date:  1995-06-01       Impact factor: 12.701

10.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

Authors:  J Wesseling; S W van der Valk; H L Vos; A Sonnenberg; J Hilkens
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

View more
  18 in total

1.  DNA methylation and histone H3-K9 modifications contribute to MUC17 expression.

Authors:  Sho Kitamoto; Norishige Yamada; Seiya Yokoyama; Izumi Houjou; Michiyo Higashi; Masamichi Goto; Surinder K Batra; Suguru Yonezawa
Journal:  Glycobiology       Date:  2010-10-06       Impact factor: 4.313

2.  MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1.

Authors:  Jennifer J Rahn; Jeffrey W Chow; Garnet J Horne; Brian K Mah; Joanne T Emerman; Pat Hoffman; Judith C Hugh
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 3.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

4.  Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop.

Authors:  Xiuling Xu; Wenshu Chen; Shuguang Leng; Mabel T Padilla; Bryanna Saxton; Julie Hutt; Mathewos Tessema; Kosuke Kato; Kwang Chul Kim; Steven A Belinsky; Yong Lin
Journal:  Carcinogenesis       Date:  2017-06-01       Impact factor: 4.944

5.  MUC1 in macrophage: contributions to cigarette smoke-induced lung cancer.

Authors:  Xiuling Xu; Mabel T Padilla; Bilan Li; Alexandria Wells; Kosuke Kato; Carmen Tellez; Steven A Belinsky; Kwang Chul Kim; Yong Lin
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

6.  Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms.

Authors:  Lixin Zhang; Anda Vlad; Christine Milcarek; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2012-09-02       Impact factor: 6.968

7.  Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells.

Authors:  Malin Bäckström; Thomas Link; Fredrik J Olson; Hasse Karlsson; Rosalind Graham; Gianfranco Picco; Joy Burchell; Joyce Taylor-Papadimitriou; Thomas Noll; Gunnar C Hansson
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

Review 8.  Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.

Authors:  Dan Ilkovitch; Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

9.  MUC1 is involved in trophoblast transendothelial migration.

Authors:  Twanda L Thirkill; Tim Cao; Michael Stout; Thomas N Blankenship; Abdul Barakat; Gordon C Douglas
Journal:  Biochim Biophys Acta       Date:  2007-04-20

10.  MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.

Authors:  Takeshi Kawano; Masaki Ito; Deepak Raina; Zekui Wu; Jacalyn Rosenblatt; David Avigan; Richard Stone; Donald Kufe
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.